INBX Inhibrx Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INBX

Price (delayed)

$34.15

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.12

Enterprise value

$1.55B

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to ...

Highlights
The company's net income has shrunk by 66% YoY and by 28% QoQ
Inhibrx's equity has shrunk by 66% QoQ and by 25% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://inhibrx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of INBX
Market
Shares outstanding
47.39M
Market cap
$1.62B
Enterprise value
$1.55B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
37.12
Price to sales (P/S)
894.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
861.48
Earnings
Revenue
$1.8M
EBIT
-$209.52M
EBITDA
-$206.56M
Free cash flow
-$197.9M
Per share
EPS
-$5.12
Free cash flow per share
-$4.2
Book value per share
$0.92
Revenue per share
$0.04
TBVPS
$6.53
Balance sheet
Total assets
$307.89M
Total liabilities
$264.39M
Debt
$210.14M
Equity
$43.5M
Working capital
$239.05M
Liquidity
Debt to equity
4.83
Current ratio
5.25
Quick ratio
4.95
Net debt/EBITDA
0.33
Margins
EBITDA margin
-11,475.7%
Gross margin
100%
Net margin
-13,408.9%
Operating margin
-12,178.9%
Efficiency
Return on assets
-84.1%
Return on equity
-590.8%
Return on invested capital
-106.7%
Return on capital employed
-83.3%
Return on sales
-11,639.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INBX stock price

How has the Inhibrx stock price performed over time
Intraday
0.41%
1 week
0.26%
1 month
-2.65%
1 year
26.53%
YTD
-10.13%
QTD
-2.32%

Financial performance

How have Inhibrx's revenue and profit performed over time
Revenue
$1.8M
Gross profit
$1.8M
Operating income
-$219.22M
Net income
-$241.36M
Gross margin
100%
Net margin
-13,408.9%
The operating margin has plunged by 107% YoY but it has soared by 68% from the previous quarter
The net margin has plunged by 102% YoY but it has soared by 69% from the previous quarter
INBX's operating income has shrunk by 70% YoY and by 32% QoQ
The company's net income has shrunk by 66% YoY and by 28% QoQ

Growth

What is Inhibrx's growth rate over time

Valuation

What is Inhibrx stock price valuation
P/E
N/A
P/B
37.12
P/S
894.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
861.48
The EPS has contracted by 41% YoY and by 20% from the previous quarter
Inhibrx's equity has shrunk by 66% QoQ and by 25% YoY
The P/S is 35% lower than the last 4 quarters average of 1373.8
The revenue has decreased by 18% YoY

Efficiency

How efficient is Inhibrx business performance
The ROS has plunged by 101% YoY but it has soared by 68% from the previous quarter
The ROE has soared by 54% YoY but it has decreased by 39% from the previous quarter
Inhibrx's ROIC has decreased by 36% YoY and by 33% from the previous quarter
The company's return on assets fell by 26% QoQ and by 17% YoY

Dividends

What is INBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INBX.

Financial health

How did Inhibrx financials performed over time
Inhibrx's total assets is 16% higher than its total liabilities
The quick ratio has plunged by 50% YoY and by 48% from the previous quarter
The current ratio has declined by 48% year-on-year and by 48% since the previous quarter
The debt to equity has soared by 198% from the previous quarter and by 35% YoY
Inhibrx's equity has shrunk by 66% QoQ and by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.